XOMA Co. (NASDAQ:XOMAO – Get Free Report) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totaling 5,711 shares, a decline of 37.6% from the December 31st total of 9,148 shares. Based on an average daily trading volume, of 4,276 shares, the days-to-cover ratio is currently 1.3 days. Based on an average daily trading volume, of 4,276 shares, the days-to-cover ratio is currently 1.3 days.
XOMA Price Performance
Shares of XOMAO stock opened at $25.39 on Friday. XOMA has a 12-month low of $23.32 and a 12-month high of $25.76. The firm has a fifty day moving average of $25.41 and a 200-day moving average of $25.43.
XOMA Company Profile
XOMA Corporation is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic antibodies. The company applies its proprietary protein engineering and antibody optimization platform to generate novel drug candidates targeting autoimmune, inflammatory and metabolic diseases. XOMA’s scientific expertise spans antibody discovery, engineering, in vitro and in vivo testing, and early‐stage clinical development.
In addition to advancing its own pipeline of antibody candidates, XOMA collaborates with pharmaceutical and biotechnology partners to provide research and development services.
Read More
- Five stocks we like better than XOMA
- Stock market legend warns: “An Ominous Day Is Coming for the Markets…”
- Another reason you need to own gold… [running out]
- Trump’s Final Shocking Act Begins February 24
- NEW: Gold makes history
- Deutsche Bank Just Raised Their Gold Target to $6,000
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.
